The development of ataxia telangiectasia mutated kinase inhibitors

Area of Science:

• Molecular Biology
• Oncology
• Drug Discovery

Background:

• Cancer treatments like radiation and genotoxic drugs are often ineffective due to DNA repair mechanisms causing resistance.
• DNA damage response (DDR) pathways, crucial for cell survival, are implicated in therapeutic resistance.
• Key kinases in DDR, including ATM, ATR, and DNA-PK, regulate signaling in response to DNA breaks.

Purpose of the Study:

• To review the development of selective inhibitors targeting ATM, ATR, and DNA-PK kinases.
• To explore the potential of these inhibitors in sensitizing cancer cells to conventional therapies.
• To highlight the application of kinase inhibitors in achieving synthetic lethality for cancer treatment.

Main Methods:

• Literature review focusing on the development of selective kinase inhibitors.
• Analysis of ATM, ATR, and DNA-PK inhibitors and their therapeutic implications.
• Exploration of the synthetic lethality concept in cancer therapy.

Main Results:

• Inhibitors of ATM, ATR, and DNA-PK show potential to overcome radio- and chemo-resistance.
• Selective kinase inhibitors can sensitize cancer cells to DNA-damaging agents.
• Development of selective inhibitors is crucial, as few are currently available.

Conclusions:

• Targeting ATM, ATR, and DNA-PK kinases represents a viable strategy to enhance cancer treatment efficacy.
• Selective inhibitors offer a pathway to overcome treatment resistance and induce cancer cell death via synthetic lethality.
• Further research into selective inhibitor development is warranted to fully exploit their therapeutic potential.